temozolomide has been researched along with pyrimidinones in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aneja, R; Banerjee, S; Jaiswal, AS; Narayan, S; Ostrov, DA; Sarkar, FH | 1 |
| Bordeaux, JS; Koon, HB; Palathinkal, DM; Sharma, TR | 1 |
| Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD | 1 |
| Bian, LG; Jiang, H; Liu, W; Pan, SJ; Pan, YX; Sun, B; Sun, QF; Zhan, SK | 1 |
| Aaby, JB; Bastholt, L; Donia, M; Duval, L; Ellebaek, E; Hoejberg, L; Køhler, UH; Schmidt, H; Svane, IM; Øllegaard, TH | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Debatin, KM; Hadzalic, A; Halatsch, ME; Karpel-Massler, G; Payer, C; Schuster, A; Selvasaravanan, KD; Siegelin, MD; Strobel, H; Westhoff, MA; Wiederspohn, N | 1 |
| Chen, AP; Das, B; Doroshow, JH; Foster, JC; Karlovich, C; Konaté, MM; Kummar, S; Leong, S; Li, MC; Lih, CJ; Meric-Bernstam, F; Moore, N; O'Sullivan Coyne, G; Palmisano, A; Piekarz, R; Polley, E; Raghav, KPS; Rosenberger, CL; Rubinstein, LV; Simon, R; Simpson, M; Sims, D; Waqar, S; Williams, PM; Zhao, Y | 1 |
2 review(s) available for temozolomide and pyrimidinones
| Article | Year |
|---|---|
Current systemic therapies for melanoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; Imidazoles; Indoles; Interferon-alpha; Interleukin-2; Ipilimumab; Melanoma; Oximes; Platinum Compounds; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides; Taxoids; Temozolomide; Vemurafenib | 2014 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
1 trial(s) available for temozolomide and pyrimidinones
| Article | Year |
|---|---|
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carboplatin; DNA, Neoplasm; Double-Blind Method; Everolimus; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasms; Pyrazoles; Pyridones; Pyrimidinones; Temozolomide; Young Adult | 2021 |
5 other study(ies) available for temozolomide and pyrimidinones
| Article | Year |
|---|---|
DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; DNA Polymerase beta; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, SCID; Molecular Targeted Therapy; Organophosphates; Pyrimidinones; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
Topics: Animals; Blood-Brain Barrier; Cell Cycle Proteins; Dacarbazine; Disease Models, Animal; DNA Damage; Glioblastoma; Humans; Mice; Nuclear Proteins; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Knockdown Techniques; Glioma; Humans; Imidazoles; Pyrimidinones; Signal Transduction; Temozolomide; Tetraspanins; TOR Serine-Threonine Kinases | 2016 |
The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Denmark; Female; Humans; Imidazoles; Ipilimumab; Male; Melanoma; Nivolumab; Oximes; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Skin Neoplasms; Survival Rate; Temozolomide | 2019 |
The limitations of targeting MEK signalling in Glioblastoma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Adhesion; Cell Death; Cell Line, Tumor; Cell Proliferation; Chorioallantoic Membrane; Drug Screening Assays, Antitumor; Glioblastoma; Humans; MAP Kinase Kinase 1; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphorylation; Pyridones; Pyrimidinones; Signal Transduction; Temozolomide; Translational Research, Biomedical | 2020 |